Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
818
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)

Vincenzo Sammartanoa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Adele Santonia Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Bruno Fredianib Rheumathology Unit, COVID Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Anna Sicuranzaa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Cencini Emanuelea Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Federico Franchic Anesthesia and Intensive Care Unit, COVID Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
,
Enrico Capochianid Hematology Unit, Azienda USL Toscana NordOvest, Center for Translational Medicine, Livorno, Italy
&
Monica Bocchiaa Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, ItalyCorrespondence[email protected]
 show all
Pages 3523-3525 | Received 06 Jul 2020, Accepted 22 Aug 2020, Published online: 09 Sep 2020

References

  • Di Gennaro F, Pizzol D, Marotta C, et al. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health. 2020;17(8):2690.
  • Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.
  • Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582.
  • Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607–613.
  • Mehta PM, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
  • Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008–3014.
  • Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
  • Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824–833.
  • Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
  • Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791.
  • Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810.
  • Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–148.
  • Naqvi K, Verstovsek S, Kantarjian H, et al. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 2011;20(8):1159–1166.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.